Sign up Australia
Proactive Investors - Run By Investors For Investors

Cynata Therapeutics achieves progress in stem cell technology

The global regenerative medicine market was worth US$18.9 billion in 2016.
Cynata Therapeutics achieves progress in stem cell technology
The patent is expected to be granted by October 2017

Cynata Therapeutics (ASX:CYP) has received the Notice of Allowance from the U.S. patent office for a patent application tied to its proprietary Cymerus™ stem cell technology.

This patent application covers an important element of Cynata’s stem cell manufacturing technology.

The technology is among the intellectual property licensed exclusively from the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) to Cynata.

Importantly, the new patent application addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for cellular therapies.

Cynata is developing cellular therapies to treat graft v host disease (GvHD), respiratory disease, cardiovascular disease and a number of other serious conditions.

The phase I clinical trial in GvHD has already commenced in the UK and Australia.

The inventors named on the patent are Dr Maxim Vodyanyk and professor Igor Slukvin, founders, advisors and shareholders of Cynata.

Cynata anticipates that the patent will be granted by October 2017, with an expiration date of 1 February 2028.

Earlier this year the company announced a breakthrough strategic agreement with Fujifilm which included the Japanese company investing A$4 million in Cynata to become its largest shareholder.

The global regenerative medicine market was worth US$18.9 billion in 2016 and is expected to grow to over US$53.7 billion by 2021.

Stem cells are considered as the cornerstone of contemporary regenerative medicine applications.



Register here to be notified of future CYP Company articles
View full CYP profile View Profile

Cynata Therapeutics Timeline

Newswire
January 19 2017

Related Articles

Microbes
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
Cells
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
ventripoint_device.png
Thu
The device can give accurate and rapid volumetric information about all four chambers of the heart

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use